

*B
1
concl.*

HB 10494, which monoclonal antibody binds specifically to an epitope present on a membrane associated antigen of human prostatic cancer epithelium and normal prostatic epithelium and which does not bind to non-prostatic antigens present in other tissues.

Please cancel claims 7, 8, 9, 10, 11, 12, 13, 14, and 15, without prejudice.

18. (Twice Amended) A process for producing monoclonal antibodies from hybridoma cultures which comprises:

- (1) taking lymphocytes from mice previously immunized with plasma membrane-enriched fractions of LNCaP cells;
- (2) fusing the [splenocytes] lymphocytes with a myeloma cell;
- (3) culturing the cell line *in vivo*; and
- (4) harvesting from ascites fluid or sera of mice injected with said hybridoma monoclonal antibodies which:
 - (a) react specifically with human prostatic cancer cells and normal prostatic cells;
 - (b) differentiate[s] prostatic carcinoma cells from other carcinoma cell types;
 - (c) does not react with normal tissues derived from bladder, urethra, testis, [ovarian] ovary, [colonic] colon, breast, thyroid, [pancreatic] pancreas or skin histotypes; and
 - (d) react[s] with a membrane associated [non-secretory] antigen of human prostate cells or tissue.

Please cancel claims 20, 21, 22, 23, and 26, without prejudice.

IN THE ABSTRACT:

Please substitute the following Abstract of the Disclosure for the present Abstract of the Disclosure: